ERBB2 and breast cancer: Another study conducted by Hamilton et al. aimed to evaluate the immunogenicity, safety, and effect of the anti-HER 2 protein [27] using a vaccine consisting of a recombinant protein combined with Lapatinib in patients with HER2-overexpressing metastatic BC and refractory to trastuzumab, which demonstrated an improved survival in BC patients (92%) after 300 days [70].